tiprankstipranks
Trending News
More News >
Metlife (MET)
NYSE:MET

Metlife (MET) AI Stock Analysis

Compare
2,947 Followers

Top Page

MET

Metlife

(NYSE:MET)

Select Model
Select Model
Select Model
Neutral 58 (OpenAI - 5.2)
Rating:58Neutral
Price Target:
$76.00
â–²(11.81% Upside)
Action:ReiteratedDate:03/06/26
The score is held back primarily by deteriorating cash-flow performance in 2025 and a clearly bearish technical trend (price below key moving averages with weak momentum). Offsetting these are a reasonable valuation with a ~3.1% dividend yield and a generally positive earnings-call outlook featuring double-digit adjusted EPS growth guidance and continued capital returns, though tempered by expected 2026 corporate headwinds and variable investment income softness.
Positive Factors
Diversified Global Franchise
MetLife’s broad geographic footprint and multi‑product model (life, group benefits, annuities, retirement) creates durable revenue diversification. Scale across markets and employer partnerships reduces single‑market dependence and supports persistent premium and fee streams through cycles.
Growing Asset Management Platform (MIM)
Elevating MIM and closing PineBridge materially expands fee‑bearing AUM, shifting mix toward higher recurring fee income and margins. A larger institutional asset manager supports revenue diversification, cross‑sell into general account assets, and a multi‑year growth runway independent of underwriting cycles.
Record Retirement & Reinsurance Origination
Strong pension risk transfer and reinsurance activity crystallizes fee income, reduces balance‑sheet liability risk, and enhances capital efficiency. Consistent large deal origination is a structural growth engine for retirement solutions and improves long‑term earnings stability.
Negative Factors
Sharp Free Cash Flow Decline
A dramatic FCF drop in 2025 signals greater volatility in cash conversion versus prior years, weakening cushion for buybacks, dividends, and organic investment. If sustained, lower cash generation could constrain capital returns and limit flexibility to fund growth or absorb investment shocks.
Variable Investment Income Sensitivity
Reliance on variable investment income creates earnings sensitivity to private markets and real estate returns. Shortfalls versus assumptions reduce distributable cash and can pressure adjusted earnings, making operating results and capital generation more cyclical and less predictable.
Moderate and Rising Leverage
Leverage has increased versus earlier years and ROE has softened, indicating less conservative balance‑sheet positioning. Higher leverage and expanding asset base reduce capital flexibility and raise sensitivity to underwriting or market shocks, potentially limiting long‑term strategic optionality.

Metlife (MET) vs. SPDR S&P 500 ETF (SPY)

Metlife Business Overview & Revenue Model

Company DescriptionMetLife, Inc., a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements. It also provides pension risk transfers, institutional income annuities, structured settlements, and capital markets investment products; and other products and services, such as life insurance products and funding agreements for funding postretirement benefits, as well as company, bank, or trust-owned life insurance used to finance nonqualified benefit programs for executives. In addition, it provides fixed, indexed-linked, and variable annuities; and pension products; regular savings products; whole and term life, endowments, universal and variable life, and group life products; longevity reinsurance solutions; credit insurance products; and protection against long-term health care services. MetLife, Inc. was founded in 1863 and is headquartered in New York, New York.
How the Company Makes MoneyMetLife generates revenue primarily through premiums collected from its insurance policies, which include life, health, and property insurance. The company also earns income from investment returns on its extensive portfolio of assets, which is comprised of bonds, equities, and real estate. Additionally, MetLife generates revenue from fees associated with its retirement and income solutions, such as annuities and pension plans. Key revenue streams include U.S. Life Insurance and Group Benefits, which provide substantial contributions to the overall earnings. Strategic partnerships with employers for group benefits and collaborations with financial advisors for retirement solutions also enhance its revenue potential. Furthermore, the company benefits from economies of scale and a diversified product offering, allowing it to mitigate risks and capitalize on various market opportunities.

Metlife Earnings Call Summary

Earnings Call Date:Feb 04, 2026
(Q4-2025)
|
% Change Since: |
Next Earnings Date:May 06, 2026
Earnings Call Sentiment Positive
The call emphasized strong operational momentum across multiple businesses, robust top-line growth, successful strategic actions (PineBridge, reinsurance, PRT origination) and achievement of key 2025 targets (adjusted EPS growth, ROE, expense efficiency, and free cash flow progress). Primary near-term concerns include a modest shortfall in variable investment income (and slightly lower-than-expected private equity/real estate returns), an anticipated 2026 drag from corporate & other, a temporary rise in the direct expense ratio due to the PineBridge acquisition, and some line-specific underwriting pressure (disability). Taken together, the positives — including record PRT origination, strong regional sales, AUM growth, capital returns, and adherence to strategic commitments — materially outweigh the headwinds described, supporting a constructive outlook.
Q4-2025 Updates
Positive Updates
Strong Quarterly Adjusted EPS Performance
Q4 adjusted earnings of $1.6B (reported $2.49/sh); excluding notable items Q4 adjusted EPS was $2.58/sh, up 24% YoY (from $2.08) and described as MetLife's highest single EPS quarter.
Full-Year Financial Targets Achieved
FY 2025 adjusted earnings (ex-notables) of ~$6.0B or $8.89/sh, up roughly 10% YoY; adjusted ROE of 16% (within 15%-17% target); two-year average free cash flow ratio of 81% (above 65%-75% target); direct expense ratio improved to 11.7%, ahead of multi-year goal.
Revenue and PRT Origination Growth
Adjusted premiums, fees and other revenues (PFOs) rose 8% to $12.8B in Q4 and rose 29% to $18.6B when retained pension risk transfer (PRT) deals included; pension risk transfer originations exceeded $14B in 2025 (MetLife's highest annual PRT total).
MetLife Investment Management (MIM) Expansion and AUM Gain
Closed PineBridge acquisition and launched MIM as a segment; year-end MIM assets under management of $742B, up from roughly $600B a year ago (~+23–24%), supporting a strategic push into asset management and expected MIM revenue growth (~+30% in 2026).
Strong International Sales Momentum — Asia & Latin America
Asia constant-currency sales +18% in 2025 (Japan and Korea contributions); Asia general account AUM +7% CC; Latin America constant-currency sales +12% and Latin America adjusted PFOs +25% CC, with LATAM Q4 adjusted earnings +13%.
Capital Deployment and Shareholder Returns
Deployed ~ $4B to support organic new business in 2025; returned ~ $2.9B via share repurchases and $1.5B in dividends (total ~$4.4B); additional $200M repurchased in January; holding company cash and cash equivalents $3.6B (within $3B–$4B target).
Record Origination and Strategic Reinsurance
RIS delivered record sales of $42B in 2025, including >$14B PRT and ~ $11B UK longevity transactions (with $7B in Q4); executed strategic reinsurance transactions including two Chariot deals (~$11B liabilities) and a Talcott risk transfer (~$10B liabilities).
Expense Efficiency and Technology Adoption
Direct expense ratio fell to 11.7% for 2025, aided by AI and process reengineering — progress described as well ahead of the five-year 100-basis-point improvement target toward an 11.3% goal.
Negative Updates
Variable Investment Income (VII) Shortfall and PE/Real Estate Returns
Q4 VII of $497M and FY VII of $1.5B fell short of the $1.7B FY target; private equity full-year return 8.2% (below expected 9%); real estate and other funds produced weaker returns, contributing to the shortfall. VII assets concentrated (~$19B total; Asia ~45%).
Corporate & Other — Large Expected 2026 Drag
Corporate and other reported an adjusted loss of $38M for 2025 (improved vs prior year) but management expects a 2026 corporate & other adjusted loss after tax in the range of $500M–$700M, representing a meaningful near-term headwind.
Higher Reported Expense Ratio in 2026 from PineBridge
The PineBridge acquisition is expected to add ~50 basis points to the direct expense ratio in 2026, raising the 2026 target to ~12.1% (a temporary headwind versus the multi-year target of 11.3%).
Q4 Disability and Nonmedical Health Pressures
Group Benefits saw weaker disability experience in Q4 driven by higher average severity, slightly higher incidents, and lower recoveries in the quarter; nonmedical health loss ratio was modestly elevated (~+1 pp in the quarter) though full-year recoveries were strong.
Notable Items and Litigation Reserve Impact
Two notable items in Q4 reduced adjusted earnings by $61M (~$0.09/sh), driven by the Mexico VAT impact and higher asbestos litigation reserves in corporate & other.
Net Income Impacted by Derivative and Trading Losses
Net income (~$800M Q4; $3.2B FY) lagged adjusted earnings primarily due to net derivative losses tied to rising long-term interest rates, FX and favorable equity markets, and normal trading-related net investment losses — underscoring market sensitivity.
Japan Surrenders and Macro Volatility
Surrenders in Japan were slightly higher in Q4 following yen depreciation (temporary); management expects surrenders to revert to long-term assumptions in 2026, but macro volatility remains a market risk to watch.
Company Guidance
The company’s near-term guidance reinforces its New Frontier commitments: management expects double‑digit adjusted EPS growth in 2026, adjusted ROE of 15%–17%, and to maintain a two‑year average free cash flow ratio of 65%–75% (supporting a five‑year free cash flow target of $25 billion, of which $4.9 billion was generated in 2025); 2026 targets include a direct expense ratio ~12.1% (PineBridge adds ~50 bps) with a 2029 target of 11.3%, favorable investment income of roughly $1.6 billion pretax, a corporate & other after‑tax loss of $500–700 million, and an effective tax rate of 24%–26% while share repurchases in 2026 are expected to be in line with 2025. Segment and product guidance includes Group Benefits PFO growth of 4%–7%, a revised group life mortality target of 83%–88% and nonmedical health interest adjusted benefit ratio of 70%–75% with Group Benefits adjusted earnings up 7%–9% in 2026; RIS retained liabilities are expected to grow 3%–5% with RIS adjusted earnings of $1.6–1.8 billion and GA spreads of 100–120 bps; Asia sales and AUM to grow mid‑single to mid‑high single digits with Asia earnings mid‑single digits; Latin America PFOs high‑single digits and adjusted earnings +6%–8% in 2026 (including ~ $50 million Mexico VAT impact); EMEA PFOs high‑single digits and a new quarterly run rate of $90–100 million in 2026; and MIM revenue growth ~30% in 2026 with MIM adjusted earnings $240–280 million (then +15%–20% p.a. in 2027–28, targeting ~32% operating margin by 2028). Additional numeric context: total VII assets ≈ $19 billion, VII return assumptions PE 9% and real estate/other 7%, year‑end MIM AUM $742 billion, holdco cash ~$3.6 billion within a $3–4 billion buffer, and US statutory NAIC RBC expected above 360%.

Metlife Financial Statement Overview

Summary
Mixed fundamentals: revenue rose ~8.9% in 2025, but net income declined (~$4.4B to ~$3.4B) with margin compression (~6.3% to ~4.4%). Balance sheet leverage is moderate (debt-to-equity ~0.68) but less conservative than earlier years and ROE cooled (~16.1% to ~11.9%). The biggest drag is cash flow: operating/FCF fell sharply in 2025 (~$15.1B to ~$2.8B), raising near-term consistency concerns despite remaining positive.
Income Statement
68
Positive
Revenue has improved meaningfully in the most recent year (2025 revenue up ~8.9% vs. 2024), but profitability has weakened. Net income fell from ~$4.4B (2024) to ~$3.4B (2025) and net margin compressed to ~4.4% from ~6.3%, reflecting a less efficient earnings profile. Longer-term results are uneven: 2021–2022 were stronger margin years, while 2023 and 2025 show clear step-downs, indicating earnings volatility.
Balance Sheet
63
Positive
Leverage is moderate for the period shown, with debt-to-equity around ~0.68 in 2024–2025 (and lower in earlier years), suggesting balance-sheet risk is manageable but not conservative versus its own history. Equity is solid at ~$28.4B (2025), and return on equity remains acceptable at ~11.9%, though down from ~16.1% in 2024 and well below the best recent years—pointing to softer capital productivity. Total assets expanded to ~$745B (2025) from ~$677B (2024), but the key watch item is the upward shift in leverage versus 2020–2021.
Cash Flow
38
Negative
Cash generation deteriorated sharply in 2025: operating cash flow and free cash flow dropped to ~$2.8B from ~$15.1B in 2024 (free cash flow down ~81%), a major negative swing. While cash flow was strong and more stable across 2020–2024 (generally ~$11B–$15B), the 2025 collapse raises concerns about volatility and the reliability of near-term cash conversion. On the positive side, free cash flow remains positive, but the year-over-year drawdown dominates the cash-flow assessment.
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue77.08B69.94B67.71B67.97B63.37B
Gross Profit28.02B19.00B17.29B18.94B16.84B
EBITDA5.72B7.37B3.92B7.97B10.13B
Net Income3.38B4.43B1.58B5.28B6.86B
Balance Sheet
Total Assets745.17B677.46B687.58B663.07B759.71B
Cash, Cash Equivalents and Short-Term Investments125.34B108.78B316.83B313.32B367.50B
Total Debt20.18B18.71B18.83B17.98B17.43B
Total Liabilities716.25B649.75B657.33B632.95B691.96B
Stockholders Equity28.40B27.45B30.02B29.88B67.48B
Cash Flow
Free Cash Flow18.11B15.12B14.26B11.37B12.83B
Operating Cash Flow18.11B15.12B14.26B11.37B12.83B
Investing Cash Flow-15.61B-11.49B-10.25B-2.62B-11.19B
Financing Cash Flow163.00M-3.13B-2.94B-9.95B-1.38B

Metlife Technical Analysis

Technical Analysis Sentiment
Negative
Last Price67.97
Price Trends
50DMA
76.07
Negative
100DMA
77.00
Negative
200DMA
77.35
Negative
Market Momentum
MACD
-2.14
Positive
RSI
28.09
Positive
STOCH
10.41
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MET, the sentiment is Negative. The current price of 67.97 is below the 20-day moving average (MA) of 73.91, below the 50-day MA of 76.07, and below the 200-day MA of 77.35, indicating a bearish trend. The MACD of -2.14 indicates Positive momentum. The RSI at 28.09 is Positive, neither overbought nor oversold. The STOCH value of 10.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MET.

Metlife Risk Analysis

Metlife disclosed 46 risk factors in its most recent earnings report. Metlife reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Metlife Peers Comparison

Overall Rating
UnderperformOutperform
Sector (68)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
$10.89B9.7420.64%0.74%3.73%17.47%
73
Outperform
$56.13B10.6013.05%2.10%2.31%15.46%
68
Neutral
$18.00B11.429.92%3.81%9.73%1.22%
65
Neutral
$11.82B18.106.63%2.22%1.80%-44.44%
63
Neutral
$6.20B6.9112.03%3.93%35.76%636.97%
60
Neutral
$32.02B11.1011.44%4.73%-19.35%-35.23%
58
Neutral
$44.32B15.5312.01%2.78%0.82%7.18%
* Financial Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
MET
Metlife
67.97
-11.82
-14.81%
AFL
AFLAC
108.71
2.61
2.46%
LNC
Lincoln National
32.61
-2.67
-7.58%
PRU
Prudential Financial
92.00
-12.71
-12.14%
GL
Globe Life
138.46
11.88
9.38%
UNM
Unum Group
72.16
-7.58
-9.51%

Metlife Corporate Events

Dividends
MetLife Confirms First-Quarter 2026 Series A Preferred Dividend
Positive
Mar 5, 2026

On March 5, 2026, MetLife, Inc. confirmed its previously announced first quarter 2026 dividend of $0.31501229 per share on its floating rate non-cumulative preferred stock, Series A, which carries a $25 per share liquidation preference. The dividend is scheduled to be paid on March 16, 2026, to shareholders of record as of February 27, 2026, with the New York Stock Exchange expected to set the ex-dividend date following this confirmatory announcement.

The confirmation underscores MetLife’s continued capital return to holders of its Series A preferred shares and signals stability in its preferred dividend policy for early 2026. The timing details, including the record date and pending ex-dividend date, provide clarity for income-focused investors and may support trading liquidity in the company’s preferred stock around the distribution period.

The most recent analyst rating on (MET) stock is a Buy with a $93.00 price target. To see the full list of analyst forecasts on Metlife stock, see the MET Stock Forecast page.

Business Operations and StrategyPrivate Placements and Financing
MetLife Issues $1 Billion Subordinated Debentures to Bolster Capital
Positive
Feb 26, 2026

On February 26, 2026, MetLife, Inc. issued $1 billion of 5.850% Fixed-to-Fixed Reset Rate Subordinated Debentures due 2056 under an existing shelf registration, using its long-standing indenture with The Bank of New York Mellon Trust Company as trustee. The securities followed underwriting and pricing agreements executed on February 24, 2026 with a syndicate led by major global banks, underscoring MetLife’s continued use of subordinated long-term debt to bolster its capital structure and diversify funding sources.

The issuance reflects MetLife’s ongoing access to public capital markets and may support regulatory capital and balance sheet flexibility important for a large insurer. By locking in a sizable 30-year subordinated tranche with a fixed-to-fixed reset structure, the company further refines its liability profile, which can have implications for credit investors and ratings considerations within the insurance and financial services sector.

The most recent analyst rating on (MET) stock is a Hold with a $82.00 price target. To see the full list of analyst forecasts on Metlife stock, see the MET Stock Forecast page.

Business Operations and StrategyExecutive/Board Changes
MetLife Expands Board With Two New Independent Directors
Positive
Feb 24, 2026

On February 24, 2026, MetLife, Inc. expanded its Board of Directors from eleven to thirteen members and elected Daniel S. Glaser and Michelle R. Seitz as new independent directors, each joining immediately. Glaser was appointed to the Audit, Compensation, and Finance and Risk Committees, while Seitz joined the Compensation, Governance and Corporate Responsibility, and Investment Committees, reflecting a targeted strengthening of the board’s oversight capabilities.

Both Glaser and Seitz will receive MetLife’s standard non-management director compensation, consisting of an annual $355,000 retainer split between common stock and cash, with pro-rated and installment-based payments for partial-year service. The appointments signal MetLife’s ongoing efforts to enhance governance, risk oversight, and strategic guidance through an expanded and independently constituted board, with potential implications for shareholders and corporate stewardship.

The most recent analyst rating on (MET) stock is a Hold with a $85.00 price target. To see the full list of analyst forecasts on Metlife stock, see the MET Stock Forecast page.

Dividends
MetLife Announces First-Quarter 2026 Preferred Stock Dividends
Positive
Feb 17, 2026

On February 17, 2026, MetLife, Inc. announced a series of preferred stock dividend declarations for the first quarter of 2026, covering its Series D, E, F and A securities. The dividends, which vary by series and structure, underscore the company’s continued capital return to preferred shareholders and reflect its current financial capacity to support these distributions.

The semi-annual dividend on Series D and quarterly dividends on Series E and F were declared with specified per-share and per-depositary-share amounts, while the floating rate Series A dividend remains subject to final confirmation that financial tests in its certificate of designations are met. All declared dividends are scheduled to be payable on March 16, 2026, to shareholders of record as of February 27, 2026, reinforcing MetLife’s ongoing engagement with income-focused investors in its capital structure.

The most recent analyst rating on (MET) stock is a Buy with a $91.00 price target. To see the full list of analyst forecasts on Metlife stock, see the MET Stock Forecast page.

Business Operations and StrategyFinancial Disclosures
MetLife Reports Strong 2025 Results and Growth Momentum
Positive
Feb 4, 2026

On February 4, 2026, MetLife reported its fourth-quarter and full-year 2025 results, highlighting solid operating momentum despite lower net income year over year. For 2025, net income declined to $3.2 billion, or $4.71 per share, but adjusted earnings per share excluding notable items rose 10% to $8.89 as premiums, fees and other revenues grew 10% to $57.6 billion and net investment income increased 6%. The company posted record Retirement & Income Solutions sales, including $14.2 billion in pension risk transfer deals and $11.1 billion of U.K. longevity reinsurance, lifted book value per share 14% to $39.02, improved expense ratios, and generated a 16% adjusted return on equity while returning nearly $4.4 billion to shareholders and maintaining holding company liquidity of $3.6 billion, suggesting stronger underlying profitability and balance sheet metrics that support its strategic push to extend market leadership and capital flexibility.

The most recent analyst rating on (MET) stock is a Buy with a $97.00 price target. To see the full list of analyst forecasts on Metlife stock, see the MET Stock Forecast page.

Business Operations and StrategyFinancial Disclosures
MetLife Elevates Investment Management in Strategic Reorganization
Positive
Jan 9, 2026

In the fourth quarter of 2025, MetLife reorganized its business to support its strategy of accelerating growth in asset management, elevating MetLife Investment Management (MIM) from Corporate & Other to a standalone reportable segment and moving MetLife Holdings largely into Corporate & Other. Certain products previously housed in the MetLife Holdings segment were reclassified into the Group Benefits and Retirement and Income Solutions segments, and the company is now structured into six segments: Group Benefits, Retirement and Income Solutions, Asia, Latin America, Europe/Middle East/Africa and MIM, with remaining activities reported in Corporate & Other. Effective January 1, 2025, MetLife also amended agreements so that MIM manages general account assets at current market fee rates, and it retroactively revised segment disclosures and its Quarterly Financial Supplement for 2024 and 2025 periods to reflect the new structure and fee arrangements, while emphasizing that these changes did not affect previously reported consolidated net income or consolidated adjusted earnings.

The most recent analyst rating on (MET) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Metlife stock, see the MET Stock Forecast page.

Business Operations and StrategyM&A Transactions
MetLife Completes PineBridge Acquisition, Expanding Global Asset Management
Positive
Dec 30, 2025

On December 30, 2025, MetLife Investment Management closed its acquisition of PineBridge Investments, creating a combined institutional asset management business with $734.7 billion in pro forma assets under management and significantly expanding MetLife’s global reach, particularly among non-U.S. clients, with a notable concentration in Asia. The deal, part of MetLife’s New Frontier strategy to accelerate growth in asset management, positions MIM as a more diversified, top-tier global asset manager, supported by a newly announced leadership team led by MIM president Brian Funk and combining senior talent from both firms, while excluding PineBridge’s private equity funds group and its China joint venture from the transaction.

The most recent analyst rating on (MET) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Metlife stock, see the MET Stock Forecast page.

Business Operations and StrategyStock BuybackFinancial DisclosuresM&A Transactions
MetLife Updates 2025 Results Outlook and Capital Plans
Positive
Dec 22, 2025

MetLife disclosed preliminary variable investment income results and capital management plans for the fourth quarter and full year 2025, ahead of its scheduled February 4, 2026 earnings release. For the quarter ending December 31, 2025, the company estimates variable investment income of $385 million to $435 million pre-tax versus a $425 million target, and for full-year 2025 it anticipates a 7.7% return on its private equity portfolio. Looking to 2026, MetLife plans to assume a 9% annual return on private equity, contributing to an estimated $1.6 billion of pre-tax variable investment income for that year, while expecting variable investment income asset balances to decline over the next one to three years. On capital deployment, MetLife intends to prioritize organic growth with about $4 billion earmarked for 2025, plus roughly $1 billion to support M&A including the pending PineBridge Investments acquisition; it also projects about $2.85 billion of common stock repurchases in 2025, including approximately $430 million in the fourth quarter, and anticipates similar buyback levels in 2026, signaling continued emphasis on shareholder returns alongside growth investments.

The most recent analyst rating on (MET) stock is a Buy with a $101.00 price target. To see the full list of analyst forecasts on Metlife stock, see the MET Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Mar 06, 2026